Why your study takes 6 months to activate, and the 5 stages where time disappears

Everyone in clinical research knows the feeling. The protocol is done, the sites are selected, and leadership wants patients enrolled yesterday. Six months later, you still haven’t dosed a single subject.

Study activation delays are one of the most persistent problems in clinical trials. The frustrating part is that most of the lost time is preventable. It disappears in handoffs, incomplete submissions, and processes that nobody owns end to end.

Here are the five stages where time gets lost, and what you can actually do about each one.

Stage 1: Feasibility and site selection

This is where the clock starts, even though most people don’t realize it.

Feasibility looks simple on paper. You send out questionnaires, collect responses, and pick sites. In practice, it’s a mess. Sites take weeks to respond. Questionnaires ask the wrong questions. The data you get back doesn’t match what you actually need to make a decision.

Where time disappears:

• Sending feasibility questionnaires to too many sites, then waiting for stragglers
• Asking about patient populations without defining clear, protocol-specific criteria
• Selecting sites based on relationships instead of actual enrollment potential
• Running feasibility and site selection sequentially instead of overlapping them

What to do:

• Set hard deadlines for feasibility responses. If a site can’t respond in two weeks, that tells you something about how they’ll perform during the trial.
• Make your feasibility questions specific to the protocol. “How many patients with condition X did you see in the last 12 months?” is better than “Do you have experience with this therapeutic area?”
• Start regulatory intelligence gathering during feasibility. Know what IRB each site uses, whether they have an active FWA (Federalwide Assurance), and what their typical review timelines look like.

Stage 2: Contracts and budgets

This is consistently the biggest bottleneck. It’s also the one with the least clinical oversight, because it lives in legal and finance departments that have their own priorities.

Where time disappears:

• Budget templates that don’t match the actual protocol procedures
• Legal redlines going back and forth for months on indemnification language
• Sites negotiating line items one at a time instead of in batches
• No single person owning the contract timeline

What to do:

• Send the clinical trial agreement and budget to sites at the same time you send the protocol. Don’t wait for regulatory documents.
• Use a fair market value analysis upfront. Most budget disputes come from sites feeling underpaid for procedures that are genuinely time-intensive. Getting the numbers right from the start saves rounds of negotiation.
• Identify your non-negotiable terms early and communicate them. Sites waste time redlining clauses that the sponsor will never change.
• Assign a dedicated contracts lead who tracks every site’s status weekly. This shouldn’t be the CRA’s (Clinical Research Associate’s) side job.

Stage 3: Regulatory and IRB submission

Regulatory submissions should be straightforward. The documents are well-defined, the process is documented, and most sites have done it hundreds of times. Yet in our experience this stage routinely runs for weeks or months longer than it should.

Where time disappears:

• Incomplete submission packages that get kicked back by the IRB (Institutional Review Board)
• Sites waiting for sponsor materials (investigator brochure updates, final informed consent templates) before they can submit
• Local IRB review committees that meet monthly, so one missed deadline means a 30-day delay
• Protocol amendments landing during the review period, forcing resubmission

What to do:

• Use a central IRB when possible. This eliminates the single biggest source of regulatory delay: waiting for dozens of local committees with different meeting schedules.
• Create a submission-ready package before you select sites. Every document the site needs should be final and available on day one of startup.
• Track IRB submission dates against committee meeting schedules. If a site’s IRB meets on the 15th and the submission deadline is the 1st, you need to plan backward from that date.

Stage 4: Essential documents

Essential documents are the collection of records that prove a site is qualified and ready to conduct the trial. Think CVs, medical licenses, training certificates, lab certifications, delegation logs, and financial disclosures.

This stage sounds administrative. It is. But it’s where weeks quietly vanish.

Where time disappears:

• Collecting documents from investigators who are busy seeing patients and don’t prioritize paperwork
• Documents that are expired, incomplete, or in the wrong format
• Back-and-forth on delegation log entries and who needs GCP (Good Clinical Practice) training
• No centralized tracking of what’s been received versus what’s outstanding

What to do:

• Send a complete checklist to sites on day one with exact specifications. “Current CV” is ambiguous. “CV dated within 2 years, signed and dated, including all clinical trial experience” is clear.
• Use a shared tracker that both the sponsor and site can see. Eliminate the “I sent it last week” emails.
• Set up automated reminders for expiring documents. A medical license that expires during the study will hold up activation.
• Assign one person at each site as the document collection point. Chasing five different people at the same institution is a time sink.

Stage 5: Site readiness and activation

This is the last mile. Everything is approved, signed, and collected. Now you need to confirm the site can actually start enrolling.

Where time disappears:

• Investigational product not shipped or not received
• Site initiation visit scheduling conflicts (getting all key personnel in the same room)
• EDC (Electronic Data Capture) system access not set up or tested
• IVRS/IXRS (Interactive Response Technology) not configured for the site
• Last-minute protocol clarifications that delay the green light

What to do:

• Start IP (Investigational Product) shipment planning during the regulatory review period. Don’t wait for full activation.
• Schedule the SIV (Site Initiation Visit) as soon as the contract is executed, even if it’s tentative. Getting on busy investigators’ calendars early matters.
• Set up all system access (EDC, IXRS, ePRO) in parallel with document collection, not after it.
• Create a site activation checklist that requires sign-off from both the sponsor and the site. Make it clear what “ready” means.

What you can do now

Study activation delays aren’t caused by one big problem. They’re caused by dozens of small ones, spread across five stages that are often managed by different people with different priorities.

The single biggest improvement you can make is to run these stages in parallel instead of sequentially. Most organizations treat startup as a waterfall: finish feasibility, then start contracts, then submit to IRB, then collect documents, then activate. That sequential approach is why activation takes six months.

Start contracts during feasibility. Prepare regulatory packages before sites are selected. Collect essential documents while the IRB reviews. Ship IP while you schedule the SIV.

None of this requires new tools or new headcount. It requires someone who owns the whole timeline, sees all five stages at once, and is willing to start the next stage before the current one is finished.